Foundry Partners LLC Makes New $3.82 Million Investment in LivaNova PLC (NASDAQ:LIVN)

Foundry Partners LLC bought a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 97,149 shares of the company's stock, valued at approximately $3,816,000. Foundry Partners LLC owned about 0.18% of LivaNova at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LIVN. CWM LLC lifted its position in shares of LivaNova by 52.3% during the 1st quarter. CWM LLC now owns 871 shares of the company's stock valued at $34,000 after buying an additional 299 shares in the last quarter. New York State Common Retirement Fund grew its position in LivaNova by 28.6% in the 1st quarter. New York State Common Retirement Fund now owns 48,290 shares of the company's stock valued at $1,897,000 after acquiring an additional 10,733 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in LivaNova by 2.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company's stock valued at $817,000 after purchasing an additional 500 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in shares of LivaNova by 6.6% during the first quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company's stock worth $1,840,000 after buying an additional 2,901 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of LivaNova by 2.1% during the first quarter. Principal Financial Group Inc. now owns 179,546 shares of the company's stock worth $7,053,000 after purchasing an additional 3,668 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on LIVN shares. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Barclays reduced their price objective on LivaNova from $56.00 to $55.00 and set an "equal weight" rating on the stock in a research note on Thursday, May 8th. Robert W. Baird lifted their target price on shares of LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Tuesday, May 13th. Finally, Wolfe Research upgraded shares of LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price on the stock in a report on Tuesday, May 20th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $59.29.

LivaNova Stock Up 0.9%

NASDAQ LIVN traded up $0.37 during trading hours on Monday, hitting $42.35. The company's stock had a trading volume of 582,385 shares, compared to its average volume of 628,913. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $57.35. The company's 50-day simple moving average is $44.77 and its two-hundred day simple moving average is $43.13. The company has a current ratio of 1.58, a quick ratio of 1.37 and a debt-to-equity ratio of 0.53. The company has a market capitalization of $2.31 billion, a PE ratio of -10.35 and a beta of 0.90.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.